LungLife AI Inc (LLAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LungLife AI Inc (LLAI) has a cash flow conversion efficiency ratio of -0.245x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.94 Million ≈ $-236.53 USD) by net assets (GBX7.93 Million ≈ $965.22 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of LungLife AI Inc for the company's overall valuation and market capitalisation.
LungLife AI Inc - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how LungLife AI Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LungLife AI Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LungLife AI Inc ranked by their cash flow conversion efficiency. See LungLife AI Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Endor AG
MU:E2N
|
691.016x |
|
ECD Automotive Design Inc
NASDAQ:ECDA
|
0.126x |
|
Worldsec Ltd
LSE:WSL
|
-0.052x |
|
Nostra Terra Oil and Gas Company PLC
LSE:NTOG
|
0.205x |
|
Cloudcoco Group PLC
LSE:CLCO
|
-2.129x |
|
Ordinary Fully Paid Deferred Settlement
AU:BCNDA
|
0.080x |
|
Nostrum Oil & Gas PLC
LSE:NOG
|
0.029x |
|
BSF Enterprise Plc
LSE:BSFA
|
-0.102x |
Annual Cash Flow Conversion Efficiency for LungLife AI Inc (2018–2023)
The table below shows the annual cash flow conversion efficiency of LungLife AI Inc from 2018 to 2023. View LLAI stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | GBX7.91 Million ≈ $962.78 |
GBX-5.02 Million ≈ $-610.79 |
-0.634x | -42.62% |
| 2022-12-31 | GBX13.14 Million ≈ $1.60K |
GBX-5.84 Million ≈ $-711.17 |
-0.445x | -18.78% |
| 2021-12-31 | GBX20.13 Million ≈ $2.45K |
GBX-7.54 Million ≈ $-917.26 |
-0.375x | -154.46% |
| 2020-12-31 | GBX19.53 Million ≈ $2.38K |
GBX-2.87 Million ≈ $-349.69 |
-0.147x | -130.12% |
| 2019-12-31 | GBX-6.80 Million ≈ $-827.11 |
GBX-3.32 Million ≈ $-404.19 |
0.489x | -29.30% |
| 2018-12-31 | GBX-3.10 Million ≈ $-377.22 |
GBX-2.14 Million ≈ $-260.72 |
0.691x | -- |
About LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more